FOR PATIENTS
FOR CLINICIANS
FOR THE PRESS
THE EXPERTS GROUP
MEDIA POOL
> SIRT > Home > Facts and figures
 

FACTS AND FIGURES

Selective Internal Radiation Therapy at a glance

 


Indications: Inoperable primary liver tumours, such as hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC),
inoperable metastases of the liver; frequently from breast or colorectal cancer, but also from neuroendocrine tumours or choroidal melanomas

Treatment regions: Europe, USA, Australia, Hong Kong, Malaysia, New Zealand, Singapore, Thailand and Israel

Patients: More than 6,000 patients treated in Germany,
over 70,000 SIRT patients worldwide

Users: Over 60 clinics and hospitals in Germany

Microspheres: Microspheres measuring 20 to 60 µm containing the radioactive beta emitter yttrium-90

Reimbursement: Generally by all statutory and private health insurance companies

 

This is where you will find a more detailed fact sheet on Selective Internal Radiation Therapy:

File PDF

Fact sheet on Selective Internal Radiation Therapy (SIRT)

 
NEWS & DATES
More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: